Gyre Therapeutics
GYRE
32 hedge funds and large institutions have $7.26M invested in Gyre Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 4 closing their positions.
92% more call options, than puts
Call options by funds: $25K | Put options by funds: $13K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 35 → 32 (-3)
48% less capital invested
Capital invested by funds: $13.9M → $7.26M (-$6.64M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
82% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 11
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.8K |
| 2 |
Morgan Stanley
New York
|
+$723 |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$241 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFA
26
Nationwide Fund Advisors
Columbus,
Ohio
| $2K | – | – | – |
|
|
PAM
27
Panagora Asset Management
Boston,
Massachusetts
| $2K | – | – | – |
|
|
BA
28
BlackRock Advisors
Wilmington,
Delaware
| $1K | – | – | – |
|
29
Geode Capital Management
Boston,
Massachusetts
| $43 | – | – | – |
|
30
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$46K | -131 | Closed |
|
|
CG
31
Cutler Group
San Francisco,
California
| – | -$13K | -39 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$1.21K | -5 | Closed |
|
GYRE Hedge Fund Activity: Q1 2016 in Review
32 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2016, worth a combined $7.26M — down 48% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GYRE and 1 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 2 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $52.8K. The largest seller was D.E. Shaw & Co, cutting an estimated $68.2K.
- 32 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2016, down from 35 in Q4 2015.
- Funds reported $7.26M of Gyre Therapeutics stock for Q1 2016, down 48% quarter-over-quarter.
- 1 fund opened new Gyre Therapeutics positions in Q1 2016 and 4 closed out, a net change of -3 holders.
- The largest Gyre Therapeutics buyer in Q1 2016 was T. Rowe Price Associates, an estimated $52.8K added.
- The largest Gyre Therapeutics seller in Q1 2016 was D.E. Shaw & Co, an estimated $68.2K sold.
Based on aggregated 13F filings for Q1 2016.